NurExone Biologic Inc. (NRX.V)
| Previous Close | 0.6000 |
| Open | 0.6200 |
| Bid | 0.5900 x N/A |
| Ask | 0.6400 x N/A |
| Day's Range | 0.6000 - 0.6500 |
| 52 Week Range | 0.1850 - 1.1900 |
| Volume | |
| Avg. Volume | 174,214 |
| Market Cap | 39.489M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.02 |
GlobeNewswireNurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
TORONTO and HAIFA, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company is pleased to announce that its common shares are now quoted for trading on the OTCQB® Venture Market (the "OTCQB") under the symbol NRXBF. The OTCQB listing enhances visibility and facilitates trading by US institutional and retail investors. As the sole public company developing therapies for spinal cord injury tre
- GlobeNewswire
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
TORONTO and HAIFA, Israel, April 19, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach" at the Exosomes of Europe conference in London in June, 2024. Dr. Shaltiel joins a
- GlobeNewswire
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
TORONTO and HAIFA, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, today provided a business update and reported financial results for the fourth quarter and financial year ended December 31, 2023. Fourth Quarter Highlights and Significant Milestones On October 26, 2023, the Company received a response from the Food and Drug Administratio
